Dr Mats Jerkeman, MD, completed his training in Clinical Oncology at Lund University, Sweden, where he is currently Professor in Clinical Oncology, and Head of Division of Oncology. His research focuses on the development of clinical trials in lymphoma, and in clinical epidemiology. He is Chairman of the Nordic Lymphoma Group, and Editor of the ESMO Guidelines of Lymphoma.

Prof. Mats Jerkeman has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, AstraZeneca, Celgene, Gilead, Incyte, Janssen and Roche.